PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34839358-11 2021 Furthermore, the combination of FGFR1 inhibitor PD173074 with ACLY inhibitor ETC-1002 markedly suppressed ONECUT2-mediated HCC metastasis. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 77-85 ATP citrate lyase Homo sapiens 62-66 33818688-5 2021 Bempedoic acid inhibits the enzyme adenosine triphosphate (ATP)-citrate lyase, which lies two steps upstream from beta-hydroxy beta-methylglutaryl-CoA reductase in the cholesterol biosynthesis pathway. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 35-77 34635427-1 2021 ATP-citrate lyase (Acly) is the target of the new class low-density lipoprotein-cholesterol (LDL-C)-lowering drug bempedoic acid (BA). 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 114-128 ATP citrate lyase Homo sapiens 0-17 34635427-1 2021 ATP-citrate lyase (Acly) is the target of the new class low-density lipoprotein-cholesterol (LDL-C)-lowering drug bempedoic acid (BA). 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 114-128 ATP citrate lyase Homo sapiens 19-23 34635427-1 2021 ATP-citrate lyase (Acly) is the target of the new class low-density lipoprotein-cholesterol (LDL-C)-lowering drug bempedoic acid (BA). 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 130-132 ATP citrate lyase Homo sapiens 0-17 34635427-1 2021 ATP-citrate lyase (Acly) is the target of the new class low-density lipoprotein-cholesterol (LDL-C)-lowering drug bempedoic acid (BA). 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 130-132 ATP citrate lyase Homo sapiens 19-23 34981622-1 2022 AIMS: Bempedoic acid inhibits ATP-citrate lyase (ACL), an enzyme in the cholesterol synthesis pathway. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 6-20 ATP citrate lyase Homo sapiens 30-47 34800002-1 2022 Bempedoic acid is an ATP citrate lyase inhibitor approved for the treatment of hypercholesterolemia. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 21-38 34435333-6 2021 Bempedoic acid, via its active coenzyme A (CoA) form, inhibits adenosine triphosphate (ATP)-citrate lyase, and reduces hepatic cholesterol synthesis through the mevalonate pathway. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 63-105 34909677-0 2021 ATP citrate lyase inhibitor Bempedoic Acid alleviate long term HFD induced NASH through improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes and improvement in NAS score. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 28-42 ATP citrate lyase Homo sapiens 0-17 34909677-3 2021 Bempedoic acid (ETC-1002), a ATP citrate lyase (ACLY) inhibitor that lowers the LDL cholesterol was recently approved by US FDA for the treatment of heterozygous familial hypercholesterolemia (HeFH) and established atherosclerotic cardiovascular disease (ASCVD). 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 29-46 34909677-3 2021 Bempedoic acid (ETC-1002), a ATP citrate lyase (ACLY) inhibitor that lowers the LDL cholesterol was recently approved by US FDA for the treatment of heterozygous familial hypercholesterolemia (HeFH) and established atherosclerotic cardiovascular disease (ASCVD). 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 48-52 34909677-3 2021 Bempedoic acid (ETC-1002), a ATP citrate lyase (ACLY) inhibitor that lowers the LDL cholesterol was recently approved by US FDA for the treatment of heterozygous familial hypercholesterolemia (HeFH) and established atherosclerotic cardiovascular disease (ASCVD). 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 16-24 ATP citrate lyase Homo sapiens 29-46 34909677-3 2021 Bempedoic acid (ETC-1002), a ATP citrate lyase (ACLY) inhibitor that lowers the LDL cholesterol was recently approved by US FDA for the treatment of heterozygous familial hypercholesterolemia (HeFH) and established atherosclerotic cardiovascular disease (ASCVD). 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 16-24 ATP citrate lyase Homo sapiens 48-52 34909677-4 2021 ACLY is one of the genes modulated in NASH patients and hence we studied the effect of ACLY inhibitor Bempedoic acid in long term HFD induced NASH animal model to understand the pharmacological benefits and the associated mechanism of action of this newly approved drug in NASH. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 102-116 ATP citrate lyase Homo sapiens 87-91 34172394-3 2021 Bempedoic acid is an oral, once-daily, ATP-citrate lyase inhibitor that significantly lowers LDL-C in patients with hypercholesterolemia when given alone or as add-on therapy to statins and/or ezetimibe. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 39-56 34448822-2 2021 Bempedoic acid, a competitive inhibitor of ATP-citrate lyase, significantly lowers LDL-C with or without background statin therapy in diverse populations. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 43-60 34075028-9 2021 In addition, the combined treatment of ACLY inhibitor ETC-1002 and IGF1R inhibitor Linsitinib dramatically suppressed HOXA13-mediated CRC metastasis. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 54-62 ATP citrate lyase Homo sapiens 39-43 34981622-1 2022 AIMS: Bempedoic acid inhibits ATP-citrate lyase (ACL), an enzyme in the cholesterol synthesis pathway. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 6-20 ATP citrate lyase Homo sapiens 49-52 35143133-3 2022 Bempedoic acid is a new oral cholesterol-lowering medication that reduces hepatic cholesterol synthesis by inhibiting the enzyme adenosine triphosphate (ATP)-citrate lyase enzyme. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 129-171 35619668-4 2022 Recently Bempedoic Acid (BA), a first in class ATP-citrate lyase inhibitor was approved for LDL-C reduction based on the CLEAR trials in which BA was superior to Placebo. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 9-23 ATP citrate lyase Homo sapiens 47-64 35619668-4 2022 Recently Bempedoic Acid (BA), a first in class ATP-citrate lyase inhibitor was approved for LDL-C reduction based on the CLEAR trials in which BA was superior to Placebo. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 25-27 ATP citrate lyase Homo sapiens 47-64 33502687-4 2021 Bempedoic acid (ETC-1002) is a new inhibitor of cholesterol synthesis that targets ATP citrate lyase (ACL). 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 83-100 33847313-1 2021 Bempedoic acid (ETC-1002) is an oral, once-daily, small molecule with a half-life of 15-24 h. It is responsible for the inhibition of ATP citrate lyase (ACLY), a cytosolic enzyme upstream of HMG-CoA reductase. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 134-151 33847313-1 2021 Bempedoic acid (ETC-1002) is an oral, once-daily, small molecule with a half-life of 15-24 h. It is responsible for the inhibition of ATP citrate lyase (ACLY), a cytosolic enzyme upstream of HMG-CoA reductase. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 153-157 33847313-1 2021 Bempedoic acid (ETC-1002) is an oral, once-daily, small molecule with a half-life of 15-24 h. It is responsible for the inhibition of ATP citrate lyase (ACLY), a cytosolic enzyme upstream of HMG-CoA reductase. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 16-24 ATP citrate lyase Homo sapiens 134-151 33847313-1 2021 Bempedoic acid (ETC-1002) is an oral, once-daily, small molecule with a half-life of 15-24 h. It is responsible for the inhibition of ATP citrate lyase (ACLY), a cytosolic enzyme upstream of HMG-CoA reductase. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 16-24 ATP citrate lyase Homo sapiens 153-157 33502687-4 2021 Bempedoic acid (ETC-1002) is a new inhibitor of cholesterol synthesis that targets ATP citrate lyase (ACL). 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 16-24 ATP citrate lyase Homo sapiens 83-100 33399194-5 2021 Bempedoic acid is a first-in-class oral adenosine triphosphate (ATP) citrate lyase inhibitor being evaluated as an additional treatment option for high-risk patients requiring further reduction in LDL-C. Bempedoic acid has been evaluated in multiple phase 2 and phase 3 trials as monotherapy or for use in combination with ezetimibe and/or statin therapy. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 40-82 33399194-5 2021 Bempedoic acid is a first-in-class oral adenosine triphosphate (ATP) citrate lyase inhibitor being evaluated as an additional treatment option for high-risk patients requiring further reduction in LDL-C. Bempedoic acid has been evaluated in multiple phase 2 and phase 3 trials as monotherapy or for use in combination with ezetimibe and/or statin therapy. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 204-218 ATP citrate lyase Homo sapiens 40-82 32763847-1 2020 Bempedoic acid, a new therapeutic for treatment of hypercholesterolemia, inhibits hepatic ATP-citrate lyase in the cholesterol synthesis pathway after its conjugation with coenzyme A. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 90-107 33276805-1 2020 BACKGROUND: Bempedoic acid is a new drug that reduces cholesterol synthesis via inhibiting ATP citrate lyase. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 12-26 ATP citrate lyase Homo sapiens 91-108 33025951-0 2020 Bempedoic acid: effect of ATP-citrate lyase inhibition on low-density lipoprotein cholesterol and other lipids. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 26-43 33025951-1 2020 Bempedoic acid is a new, first-in-class oral ATP-citrate lyase (ACLY) inhibitor that has to be converted to its CoA thioester before it inhibits ACLY. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 45-62 33025951-1 2020 Bempedoic acid is a new, first-in-class oral ATP-citrate lyase (ACLY) inhibitor that has to be converted to its CoA thioester before it inhibits ACLY. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 64-68 33025951-1 2020 Bempedoic acid is a new, first-in-class oral ATP-citrate lyase (ACLY) inhibitor that has to be converted to its CoA thioester before it inhibits ACLY. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 145-149 32980290-2 2020 OBJECTIVE: The objective of this study was to describe the safety profile of bempedoic acid, an oral, first-in-class, adenosine triphosphate (ATP)-citrate lyase inhibitor that significantly reduces low-density lipoprotein cholesterol (LDL-C) levels by 17.4%-28.5% vs placebo. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 77-91 ATP citrate lyase Homo sapiens 118-160 32564642-0 2020 Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 32-49 31499095-3 2020 Among current ACLY inhibitors, Bempedoic acid (ETC-1002) is a first-in-class, prodrug-based direct competitive inhibitor of ACLY which regulates lipid metabolism by upregulating hepatic LDL receptor (LDLr) expression and activity. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 31-45 ATP citrate lyase Homo sapiens 124-128 31499095-3 2020 Among current ACLY inhibitors, Bempedoic acid (ETC-1002) is a first-in-class, prodrug-based direct competitive inhibitor of ACLY which regulates lipid metabolism by upregulating hepatic LDL receptor (LDLr) expression and activity. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 31-45 ATP citrate lyase Homo sapiens 14-18 31499095-3 2020 Among current ACLY inhibitors, Bempedoic acid (ETC-1002) is a first-in-class, prodrug-based direct competitive inhibitor of ACLY which regulates lipid metabolism by upregulating hepatic LDL receptor (LDLr) expression and activity. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 47-55 ATP citrate lyase Homo sapiens 14-18 31499095-3 2020 Among current ACLY inhibitors, Bempedoic acid (ETC-1002) is a first-in-class, prodrug-based direct competitive inhibitor of ACLY which regulates lipid metabolism by upregulating hepatic LDL receptor (LDLr) expression and activity. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 47-55 ATP citrate lyase Homo sapiens 124-128 30922146-2 2019 Bempedoic acid, a prodrug that is activated by a hepatic enzyme not present in skeletal muscle, inhibits ATP -citrate lyase, an enzyme upstream of beta-hydroxy beta-methylglutaryl-coenzyme A reductase in the cholesterol biosynthesis pathway. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 105-123 31906686-10 2019 The small molecule ATP citrate lyase inhibitor, bempedoic acid, decreases LDL-C by a further 20 % over and above the reduction achievable by a statin. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 48-62 ATP citrate lyase Homo sapiens 19-36 30865796-1 2019 BACKGROUND: Short-term studies have shown that bempedoic acid, an inhibitor of ATP citrate lyase, reduces levels of low-density lipoprotein (LDL) cholesterol. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 47-61 ATP citrate lyase Homo sapiens 79-96 29939848-0 2019 Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor: Review of a First-in-Class Medication with Potential Benefit in Statin-Refractory Cases. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 27-44 29939848-0 2019 Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor: Review of a First-in-Class Medication with Potential Benefit in Statin-Refractory Cases. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 16-24 ATP citrate lyase Homo sapiens 27-44 30586346-1 2019 PURPOSE OF REVIEW: Bempedoic acid has emerged as a potent inhibitor of ATP-citrate lyase (ACLY), a target for the reduction of LDL cholesterol (LDL-C). 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 19-33 ATP citrate lyase Homo sapiens 71-88 30586346-1 2019 PURPOSE OF REVIEW: Bempedoic acid has emerged as a potent inhibitor of ATP-citrate lyase (ACLY), a target for the reduction of LDL cholesterol (LDL-C). 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 19-33 ATP citrate lyase Homo sapiens 90-94 30586346-3 2019 RECENT FINDINGS: The liver-specific activation of bempedoic acid inhibits ACLY, a key enzyme linking glucose catabolism to lipogenesis by catalyzing the formation of acetyl-CoA from mitochondrial-derived citrate for de novo synthesis of fatty acids and cholesterol. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 50-64 ATP citrate lyase Homo sapiens 74-78 28059952-6 2017 A lipid-regulating compound, bempedoic acid, was discovered to potently inhibit ACLY, and in animal models, it prevents dyslipidemia and attenuates atherosclerosis. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 29-43 ATP citrate lyase Homo sapiens 80-84 28059952-8 2017 SUMMARY: The efficacy of bempedoic acid as an LDL-C-lowering agent has validated ACLY inhibition as a therapeutic strategy. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 25-39 ATP citrate lyase Homo sapiens 81-85 27663902-0 2016 Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 16-24 ATP citrate lyase Homo sapiens 59-76 27663902-1 2016 Bempedoic acid (ETC-1002), a novel therapeutic approach for low-density lipoprotein cholesterol (LDL-C) lowering, inhibits ATP citrate lyase (ACL), an enzyme involved in fatty acid and cholesterol synthesis. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 123-140 27663902-1 2016 Bempedoic acid (ETC-1002), a novel therapeutic approach for low-density lipoprotein cholesterol (LDL-C) lowering, inhibits ATP citrate lyase (ACL), an enzyme involved in fatty acid and cholesterol synthesis. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 142-145 27663902-1 2016 Bempedoic acid (ETC-1002), a novel therapeutic approach for low-density lipoprotein cholesterol (LDL-C) lowering, inhibits ATP citrate lyase (ACL), an enzyme involved in fatty acid and cholesterol synthesis. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 16-24 ATP citrate lyase Homo sapiens 123-140 27663902-1 2016 Bempedoic acid (ETC-1002), a novel therapeutic approach for low-density lipoprotein cholesterol (LDL-C) lowering, inhibits ATP citrate lyase (ACL), an enzyme involved in fatty acid and cholesterol synthesis. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 16-24 ATP citrate lyase Homo sapiens 142-145 27892461-0 2016 Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 47-61 ATP citrate lyase Homo sapiens 15-32 27892461-2 2016 Bempedoic acid (ETC-1002) is a small molecule intended to lower LDL-C in hypercholesterolemic patients, and has been previously shown to modulate both ATP-citrate lyase (ACL) and AMP-activated protein kinase (AMPK) activity in rodents. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 151-168 27892461-2 2016 Bempedoic acid (ETC-1002) is a small molecule intended to lower LDL-C in hypercholesterolemic patients, and has been previously shown to modulate both ATP-citrate lyase (ACL) and AMP-activated protein kinase (AMPK) activity in rodents. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 170-173 27892461-2 2016 Bempedoic acid (ETC-1002) is a small molecule intended to lower LDL-C in hypercholesterolemic patients, and has been previously shown to modulate both ATP-citrate lyase (ACL) and AMP-activated protein kinase (AMPK) activity in rodents. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 16-24 ATP citrate lyase Homo sapiens 151-168 27892461-2 2016 Bempedoic acid (ETC-1002) is a small molecule intended to lower LDL-C in hypercholesterolemic patients, and has been previously shown to modulate both ATP-citrate lyase (ACL) and AMP-activated protein kinase (AMPK) activity in rodents. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 16-24 ATP citrate lyase Homo sapiens 170-173 27663902-0 2016 Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-14 ATP citrate lyase Homo sapiens 59-76 26073398-5 2015 ETC-1002 is a small molecule inhibitor of ATP citrate lyase that also activates 5"-adenosine monophosphate-activated protein kinase, effectively reducing low-density lipoprotein cholesterol and inducing some other positive metabolic changes. 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 0-8 ATP citrate lyase Homo sapiens 42-59